KalVista Pharmaceuticals (KALV) Enterprise Value (2016 - 2024)
Historic Enterprise Value for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to -$268.3 million.
- KalVista Pharmaceuticals' Enterprise Value changed N/A to -$268.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$268.3 million, marking a year-over-year change of. This contributed to the annual value of -$210.4 million for FY2024, which is N/A changed from last year.
- Latest data reveals that KalVista Pharmaceuticals reported Enterprise Value of -$268.3 million as of Q4 2024.
- KalVista Pharmaceuticals' Enterprise Value's 5-year high stood at -$50.3 million during Q1 2021, with a 5-year trough of -$268.3 million in Q4 2024.
- Over the past 4 years, KalVista Pharmaceuticals' median Enterprise Value value was -$91.9 million (recorded in 2020), while the average stood at -$117.5 million.
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 4021.68% in 2020, then plummeted by 4138.91% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Enterprise Value stood at -$55.9 million in 2020, then rose by 9.96% to -$50.3 million in 2021, then crashed by 105.07% to -$103.2 million in 2023, then tumbled by 160.09% to -$268.3 million in 2024.
- Its last three reported values are -$268.3 million in Q4 2024, -$135.8 million for Q4 2024, and -$174.3 million during Q3 2024.